Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1878-1888

  Carey, Dianne ^a   Amin, Janaki ^a   Boyd, Mark ^a   Petoumenos, Kathy ^a   Emery, Sean ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral therapy; HDL; LDL

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77955622847     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq231     Document Type: Review

References (42)

1. Riddler SA, Li X, Chu H et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8: 280-7.
2. Grunfeld C, Pang M, Doerrler W et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52.
3. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82.
4. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
5. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection [see Comment]. J Acquir Immune Defic Syndr 2000; 23: 35-43.
6. Thiébaut R, Daucourt V, Mercie P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis 2000; 31: 1482-7.
7. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
8. Lakka TA, Lakka HM, Salonen R et al. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001; 154: 497-504.
9. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
10. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
11. Wand H, Calmy A, Carey DL et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445-53.
12. Iloeje UH, Yuan Y, L'Italien G et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
13. Friis-Møller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
14. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
15. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17: 2603-14.
16. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
17. Malan DR, Krantz E, David N et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-7.
18. Molina J-M, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-55.
19. Johnson M, Grinsztejn B, Rodriguez C et al. 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711-8.
20. Cohen C, Nieto-Cisneros L, Zala C et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res & Opin 2005; 21: 1683-92.
21. Moyle G, Girard P, Andrade J et al. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48-week primary analysis of the 96-week multicenter, open-label, randomised, prospective REAL Study. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract MOPDB103. Available at http://www.iasociety.org/AbstractSearch.aspx
22. Calza L, Manfredi R, Farneti B et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22: 54-9.
23. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6: 421-5.
24. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services December 1 2009; 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (2 February 2010, date last accessed).
25. Higgins J, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009; www.cochrane-handbook.org.
26. Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group, 2001.
27. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths. Lancet 2007; 370: 1829-39.
28. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 685-94.
29. Mallolas J, Podzamczer D, Milinkovic A et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51: 29-36.
30. Delfraissy J, Moreno S, Sanz-Moreno J et al. Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2 NRTIs) in patients with VL < 50 c/mL after induction with ATV/r + 2 NRTIs: study AI424136. J Int AIDS Soc 2008; 11: Suppl 1: 22.
31. Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
32. Shlay JC, Bartsch G, Peng G et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitorbased strategy. J Acquir Immune Defic Syndr 2007; 44: 506-17.
33. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-74.
34. Young J, Weber R, Rickenbach M et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005; 10: 585-91.
35. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
36. Pozniak AL, Gallant JE, DeJesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-40.
37. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis [see Comment]. Int J Epidemiol 2005; 34: 79-87.
38. Chan A-W, Hrobjartsson A, Haahr MT et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-65.
39. Becker JT, Kingsley L, Mullen J et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73: 1292-9.
40. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.
41. Shikuma CM, Yang Y, Glesby MJ et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007; 44: 540-50.
42. Silverberg MJ, Leyden W, Hurley L et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150: 301-13.